BOLD Company Profile and Key Details

NASDAQ : BOLD

Boundless Bio

$2.50

0.02+0.81%

Open: 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Boundless Bio, Inc. (BOLD) stock surged +0.81%, trading at $2.50 on NASDAQ, up from the previous close of $2.48. The stock opened at $2.50, fluctuating between $2.45 and $2.60 in the recent session.

Stock Snapshot

2.48

Prev. Close

56.19M

Market Cap

2.45

Day Low

-1

P/E Ratio

-2.5

EPS (TTM)

N/A

Cash Flow per Share

2.5

Open

22.47M

Number of Shares

2.6

Day High

73.54%

Free Float in %

N/A

Book Value

143.9K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 02, 2026	2.50	2.60	2.45	2.50	139.28K
Jul 01, 2026	2.53	2.53	2.46	2.48	329.17K
Jun 30, 2026	2.71	2.72	2.49	2.50	687.97K
Jun 29, 2026	2.56	2.58	2.39	2.45	291.67K
Jun 26, 2026	2.50	2.61	2.48	2.56	238K
Jun 25, 2026	2.62	2.63	2.42	2.51	888.49K
Jun 24, 2026	2.60	2.79	2.58	2.60	2.46M
Jun 23, 2026	2.40	2.75	2.25	2.60	65.12M
Jun 22, 2026	1.44	1.47	1.40	1.40	171.27K
Jun 18, 2026	1.41	1.43	1.41	1.43	80.18K
Jun 17, 2026	1.45	1.45	1.40	1.40	64.98K
Jun 16, 2026	1.43	1.44	1.40	1.41	141.12K
Jun 15, 2026	1.45	1.45	1.40	1.40	23.01K
Jun 12, 2026	1.41	1.41	1.40	1.41	9.75K
Jun 11, 2026	1.41	1.41	1.38	1.39	37.5K
Jun 10, 2026	1.39	1.41	1.38	1.38	52.56K
Jun 09, 2026	1.45	1.45	1.38	1.40	115.2K
Jun 08, 2026	1.47	1.47	1.41	1.43	70.99K
Jun 05, 2026	1.49	1.49	1.39	1.42	60.18K
Jun 04, 2026	1.43	1.49	1.43	1.47	72.16K

Contact Details

San Diego, CA 92121

United States

https://boundlessbio.com 858 766 9912

About Company

Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.

Stock Peers

ARGX

30.18002+3.32%

argenx SE$939.68 REGN

29.55+4.73%

Regeneron Pharmaceuticals, Inc.$654.27 UTHR

8.75993+1.60%

United Therapeutics Corporation$555.91 MDGL

13.71+2.67%

Madrigal Pharmaceuticals, Inc.$528.10 VRTX

30.03+6.03%

Vertex Pharmaceuticals Incorporated$528.04 KRYS

3.49+0.94%

Krystal Biotech, Inc.$375.07 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 LGND

7.54+2.42%

Ligand Pharmaceuticals Incorporated$319.55 PRAX

-1.08-0.34%

Praxis Precision Medicines, Inc.$318.52 ALNY

11.11+3.68%

Alnylam Pharmaceuticals, Inc.$312.78

Company Overview

Boundless Bio, Inc. (NASDAQ:BOLD) closed at $2.50 USD, gaining $0.02 (0.81%) from the previous close of $2.48. The stock is currently mid-range between its 52-week high and low $0.96 and $2.79. With a market capitalization of about $56.19 million, Boundless Bio, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.40). Key stats such as the average daily volume over the past year has been around 1.35 million shares, volume is running light vs its 52-week average. Headquartered in San Diego, CA, Boundless Bio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Zachary Hornby, the company employs approximately 64 people and listed since July 20, 2016. Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors.

Technical Performance

BOLD has shown mixed momentum, losing -0.81% over the past week and -10.22% over the past quarter, though year-to-date performance is up 2.5%. Short-term trend indicators are bullishly aligned (SMA20 1.78%, SMA50 -2.86%, SMA200 -3.82%). The stock’s 14-day RSI is 48.9 (neutral), while the ATR of 0.05 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -43.41% below its high and over 20.68% above its low. Average 10-day trading volume of 429.09 thousand shares is below the 3-month average of 1.42 million, indicating normal recent market interest.

Valuation Metrics

Boundless Bio, Inc. trades at a P/E ratio of -1.0, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.65 suggesting the stock is closer to book value. The P/FCF stands at -1.18, also above market averages.

Dividend & Fair Value

Boundless Bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$1.39. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Wall Street analysts project EPS growth of 35.77% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $4.00 to $4.00. The high target offers 60.0% upside. The low target suggests 60.0% downside. The mean target is $4.00. This offers 60.0% upside. Boundless Bio, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 08, 2026, missed forecasts by 4.05%. The prior quarter beat by 31.82%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in March 27, 2025.

Shareholding & Insider Activity

Boundless Bio, Inc. has 22.46 million shares outstanding. The public float is 15.33 million shares, elevated short interest at 0.05% of float. This equals 6.06 thousand shares. The short ratio is 0.05 days. Institutional investors hold 63.01% of the float. Insiders own 11.4%. SILVERSTEIN JONATHAN holds 4.80 million shares, ORBIMED ADVISORS LLC has 3.54 million shares and TANG KEVIN has 2.64 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Boundless Bio has not generated any revenue.
On valuation metrics, Boundless Bio trades at a P/E of -1.00, P/S of 0.00 and P/B of 0.65. The current ratio is 9.87 and quick ratio is 9.87. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -609.83 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.56, supported by a cash flow-to-debt ratio of -0.98.

Price Forecast & Outlook

Our AI price prediction model suggests that Boundless Bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 10.0%, with price expected at $2.75 by July 16, 2026, within a range of $2.34 to $3.16 3-Month Outlook: Projected rise of 149.6%, reaching $6.24 by September 30, 2026, with a range of $6.07 to $6.46. 1-Year Outlook: Projected loss of -3.6%, with price at $2.41 by July 02, 2027, within a range of $2.02 to $2.89.

Key Takeaways

Boundless Bio, Inc. (NASDAQ:BOLD) shares are flat 2.5% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Boundless Bio, Inc. trading at a premium to the broader market with a P/E of -1.0. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $4.00, suggesting 60.0% upside. Our AI forecast model points to short-term strength (10.0% over two weeks), a medium-term rise (149.6% over three months), and a longer-term loss (-3.6% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Boundless Bio, Inc. (BOLD) stock price?

Boundless Bio, Inc. (NASDAQ: BOLD) stock price is $2.50 in the last trading session. During the trading session, BOLD stock reached the peak price of $2.60 while $2.45 was the lowest point it dropped to. The percentage change in BOLD stock occurred in the recent session was 0.81% while the dollar amount for the price change in BOLD stock was $0.02.

BOLD's industry and sector of operation?

The NASDAQ listed BOLD is part of Biotechnology industry that operates in the broader Healthcare sector. Boundless Bio, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of BOLD?

No Data

How BOLD did perform over past 52-week?

BOLD's closing price is 160.15% higher than its 52-week low of $0.96 where as its distance from 52-week high of $2.79 is -10.39%.

How many employees does BOLD have?

Number of BOLD employees currently stands at 64.

Link for BOLD official website?

Official Website of BOLD is: https://boundlessbio.com

How do I contact BOLD?

BOLD could be contacted at phone 858 766 9912 and can also be accessed through its website. BOLD operates from 9880 Campus Point Drive, San Diego, CA 92121, United States.

How many shares of BOLD are traded daily?

BOLD stock volume for the day was 143.9K shares. The average number of BOLD shares traded daily for last 3 months was 1.35M.

What is the market cap of BOLD currently?

The market value of BOLD currently stands at $56.19M with its latest stock price at $2.50 and 22.47M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	64
Beta	0.97
Sales or Revenue	N/A
5Y Sales Change%	0%
Fiscal Year Ends	N/A
Sector	Healthcare
Industry	Biotechnology

BOLD Company Profile and Key Details

Boundless Bio

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Financial & Profitability Overview

Earnings & Analyst Outlook

Company Overview

Shareholding & Insider Activity

Dividend & Fair Value

Price Forecast & Outlook

Key Takeaways

Valuation Metrics